Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
J Diabetes Res. 2020 Feb 27;2020:5214751. doi: 10.1155/2020/5214751. eCollection 2020.
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia. It affects millions of people globally. In spite of many antidiabetic drugs that are available, an adequate level of control remains challenging. Hydroxychloroquine is an immunomodulatory drug that has been used for the treatment of malaria and autoimmune diseases. There is an emerging evidence that suggests its beneficial effect against diabetes mellitus. Therefore, this systematic review is aimed at discoursing the role of hydroxychloroquine against diabetes mellitus and its potential mechanisms of actions.
A systematic and manual searching was carried out to retrieve relevant articles (preclinical and clinical studies) published from January 2014 to July 2019. Electronic databases including PubMed and Scopus as well as clinicaltrials.gov have been searched using different searching terms: "hydroxychloroquine," "diabetes mellitus," "hyperglycemia," and "insulin resistance." The MeSH terms (PubMed) and text words were combined with "AND" or "OR." In addition, manual searching of Google Engine and Google Scholar was conducted. Quality assessment of all the included studies was performed using CAMARADES (preclinical studies) and the Newcastle-Ottawa Scale and Cochrane Collaboration's tools (clinical studies).
A total of eighteen studies (three experimental and fifteen clinical studies) were found to be eligible for the present systematic review. Among the included clinical studies (six randomized control trials, five observational studies, and four cohort studies), about 55,776 study participants were involved. Most of these studies showed significant improvement of lipid profile and insulin levels and substantial diminution of hemoglobin A1c, fasting plasma glucose, and postprandial blood glucose levels. Reduction in lysosomal degradation of the internal insulin-insulin receptor complex and enhancement in insulin sensitivity and adiponectin levels are some of the hypothesized mechanisms for the antidiabetic effect of hydroxychloroquine.
The current review provides preliminary evidence for potential antidiabetic properties of hydroxychloroquine. Though the provided available data were promising, further clinical trials and mechanistic studies are needed to determine its long-term effects.
糖尿病是一种以持续性高血糖为特征的慢性代谢性疾病。它影响着全球数百万人。尽管有许多抗糖尿病药物可供使用,但仍难以达到足够的控制水平。羟氯喹是一种免疫调节剂,已用于治疗疟疾和自身免疫性疾病。有新的证据表明,它对糖尿病有有益的作用。因此,本系统评价旨在论述羟氯喹对糖尿病的作用及其潜在的作用机制。
我们进行了系统和手动搜索,以检索 2014 年 1 月至 2019 年 7 月期间发表的相关文章(临床前和临床研究)。我们使用不同的检索词在电子数据库(PubMed 和 Scopus)以及临床试验.gov 上进行了搜索:“羟氯喹”、“糖尿病”、“高血糖”和“胰岛素抵抗”。PubMed 使用 MeSH 术语和文本词,并与“AND”或“OR”结合使用。此外,我们还对 Google 引擎和 Google Scholar 进行了手动搜索。使用 CAMARADES(临床前研究)和纽卡斯尔-渥太华量表以及 Cochrane 协作工具(临床研究)对所有纳入的研究进行了质量评估。
共发现 18 项研究(3 项实验研究和 15 项临床研究)符合本系统评价的纳入标准。在纳入的临床研究(6 项随机对照试验、5 项观察性研究和 4 项队列研究)中,约有 55776 名研究参与者。这些研究大多显示出脂质谱和胰岛素水平的显著改善,以及血红蛋白 A1c、空腹血浆葡萄糖和餐后血糖水平的显著降低。减少溶酶体对内源胰岛素-胰岛素受体复合物的降解以及增强胰岛素敏感性和脂联素水平是羟氯喹抗糖尿病作用的一些假设机制。
本综述提供了羟氯喹具有潜在抗糖尿病特性的初步证据。尽管现有数据很有前景,但仍需要进一步的临床试验和机制研究来确定其长期效果。